BioCentury
ARTICLE | Company News

Angiochem advances ANG1005 for cancer

October 21, 2013 11:39 PM UTC

Angiochem Inc. (Montreal, Quebec) said it will continue to develop ANG1005 (formerly GRN1005) based on additional Phase II data showing the compound produced responses in breast cancer patients with brain metastases. Last year, Geron Corp. (NASDAQ:GERN) discontinued development of ANG1005 and returned rights to the compound to Angiochem after a planned interim futility analysis of 30 patients in the trial found ANG1005 produced no confirmed intracranial responses, the primary endpoint. However, Angiochem said that in 80 HER2-positive and HER2-negative patients in the intent-to-treat (ITT) population of the trial, ANG1005 produced 14 partial responses and 35 cases of stable disease. Data were presented at the Molecular Targets and Cancer Therapeutics meeting in Boston (see BioCentury Extra, Dec. 3, 2012). ...